The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Offer details
Expected size of offer (M): NIL
Expected first date of trading: 03/06/2014
Market: AIM
Location of address at which admission document will be available: www.biofrontera.com/en/investors The Admission Document will contain full details about the Company and the admission of its securities.
Date at which admission document will be available: -

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): finnCap Ltd
Nominated Broker (AIM Companies): finnCap Ltd
Financial PR Advisors: -

Company details
Name Role
Hermann Luebbert, PhD Chairman of the Management Board and Chief Executive Officer
Thomas Schaffer Member of the Management Board and Chief Financial Officer
Jürgen Baumann Chairman of the Supervisory Board
Andreas Fritsch Member of the Supervisory Board
Dr. Ulrich Granzer Member of the Supervisory Board
Ulrike Kluge Member of the Supervisory Board
Alfred Neimke Member of the Supervisory Board
Prof. Dr. rer. nat. Bernd Wetzel Vice Chairman of the Supervisory Board

Facts and Figures
Fiscal year end: 31 December
Incorporated in: Germany
Website URL: www.biofrontera.com/en/investors
space
Description of business:
Biofrontera is a biopharmaceutical company operating out of Germany specialising in the development of medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Biofrontera's main product is Ameluz, a prescription drug approved for use in Europe for the treatment of Actinic Keratosis with photodynamic therapy. The Company is looking to further develop Ameluz for use ...

Person(s) interested:
Before and after Admission: Maruho Deutschland GmbH - 20.1% MM Familien KG - 10.3% Prof. Dr. Ulrich Abshagen - 4.6% Universal Investment Gesellschaft GmbH - 4.4% Hermann Luebbert - 3.1%


Biofrontera AG

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds